Assembly Biosciences Inc ASMB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ASMB is a good fit for your portfolio.
News
-
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
-
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
-
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
-
Thinking about buying stock in Assembly Biosciences, Olink Holding, Nkarta, Scisparc, or Aurora Mobile?
-
Assembly Biosciences Shares Soar Premarket on Gilead Pact
-
Gilead Taking Stake in Assembly Bio Under Antiviral Collaboration
-
Gilead to pay Assembly an initial $100 million as part of 12-year partnership to develop antiviral drugs
Trading Information
- Previous Close Price
- $0.70
- Day Range
- $0.70–0.73
- 52-Week Range
- $0.64–1.78
- Bid/Ask
- $0.72 / $0.72
- Market Cap
- $47.24 Mil
- Volume/Avg
- 43,060 / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 68
- Website
- https://www.assemblybio.com
Valuation
|
Metric
|
ASMB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.88 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ASMB
|
|---|---|
Quick Ratio | 6.48 |
Current Ratio | 6.96 |
Interest Coverage | — |
Quick Ratio
ASMB
Profitability
|
Metric
|
ASMB
|
|---|---|
Return on Assets (Normalized) | −78.29% |
Return on Equity (Normalized) | −94.43% |
Return on Invested Capital (Normalized) | −94.35% |
Return on Assets
ASMB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vxcj | $456.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hsxxh | $91.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dkpdwh | $89.8 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Wnzhdrx | $40.2 Bil | |
MRNA
| Moderna Inc | Vcknv | $29.6 Bil | |
ARGX
| argenx SE ADR | Nycrm | $26.4 Bil | |
BNTX
| BioNTech SE ADR | Prkd | $23.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cwmdgj | $21.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jwtsst | $17.2 Bil | |
INCY
| Incyte Corp | Dldrfs | $12.2 Bil |